Hook effect: a case study of a giant invasive prolactinoma in pregnancy with falsely low serum prolactin

Rahul D. Nikumbhe; Bhimrao G. Kamble; Aniket D. Agarkar; Sufiyan A. Khan

doi:10.18203/2320-6012.ijrms20250268

Authors

Rahul D. Nikumbhe Department of Medicine, Pandit Madan Mohan Malviya Shatabdi Hospital, Govandi, Mumbai, Maharashtra, India
Bhimrao G. Kamble Department of Medicine, Pandit Madan Mohan Malviya Shatabdi Hospital, Govandi, Mumbai, Maharashtra, India
Aniket D. Agarkar Department of Medicine, Pandit Madan Mohan Malviya Shatabdi Hospital, Govandi, Mumbai, Maharashtra, India
Sufiyan A. Khan Department of Medicine, Pandit Madan Mohan Malviya Shatabdi Hospital, Govandi, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20250268

Keywords:

Prolactinoma, Pituitary adenoma, Prolactin, Optic chiasma, Galactorrhoea, Macroadenoma

Abstract

Prolactinoma is the most common type of pituitary adenoma characterized by excessive production of the hormone prolactin, while the majority of tumours are benign. A small percentage can develop into more aggressive macro adenocarcinomas, which pose a significant challenge in management and prognosis. High estrogen levels during pregnancy lead to an increase in the size of prolactinomas leading to compression of optic chiasma. Eventually, it manifests as visual symptoms and headaches. Pharmacotherapy with dopamine agonists is the treatment of choice and multidisciplinary management results in successful outcomes. The present study describes A 28-year-old female with a 36-week pregnancy presenting with complaints of neck pain, headache, and blurring of vision to our hospital. On inquiry, the patient gave a history of galactorrhoea so a magnetic resonance imaging (MRI) brain was done. MRI brain was suggestive of a giant 18×9×8 mm macroadenoma.

Metrics

Metrics Loading ...

References

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88.

Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265-73. DOI: https://doi.org/10.1111/j.1365-2265.2006.02562.x

Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2024;20(1):62. DOI: https://doi.org/10.1038/s41574-023-00916-2

Petakov MS, Damjanović SS, Nikolić-Durović MM, Dragojlović ZL, Obradović S, Gligorović MS, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest. 1998;21(3):184-8. DOI: https://doi.org/10.1007/BF03347299

Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery. 1998;42(4):913-5. DOI: https://doi.org/10.1097/00006123-199804000-00126

Frieze TW, Mong DP, Koops MK. "Hook effect" in prolactinomas: case report and review of literature. Endocr Pract. 2002;8(4):296-303. DOI: https://doi.org/10.4158/EP.8.4.296

St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf). 1996;44(3):305-9. DOI: https://doi.org/10.1046/j.1365-2265.1996.663486.x

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. DOI: https://doi.org/10.1210/jc.2010-1692

dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011;14:259-65. DOI: https://doi.org/10.1007/s11102-010-0290-z

Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1:33. DOI: https://doi.org/10.1186/2046-4053-1-33

Bayrak A, Saadat P, Mor E, Chong L, Paulson RJ, Sokol RZ. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005;84(1):181-5. DOI: https://doi.org/10.1016/j.fertnstert.2005.01.102

Cole TG, Johnson D, Eveland BJ, Nahm MH. Cost-effective method for detection of "hook effect" in tumor marker immunometric assays. Clin Chem. 1993;39(4):695-6. DOI: https://doi.org/10.1093/clinchem/39.4.695a